Creo Medical GroupCMEOF 52 PE Ratio (TTM) is 14.29 as of Jul. 02, 2026, which is 9% above its 10-year median of 13.13. GuruFocus rates CMEOF with a GF Score™ of 52/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 435 Medical Devices & Instruments companies, Creo Medical Group ranks better than 79.77% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-02), Creo Medical Group's share price is
$0.20.
Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Therefore, Creo Medical Group's PE Ratio (TTM) for today is 14.29.
The historical rank and industry rank for Creo Medical Group's PE Ratio (TTM) or its related term are showing as below:
CMEOF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 10.15 Med: 13.13 Max: 17.75
Current: 13.5
During the past 11 years, the highest PE Ratio (TTM) of Creo Medical Group was 17.75. The lowest was 10.15. And the median was 13.13.
CMEOF's PE Ratio (TTM) is ranked better than 79.77% of 435
companies
in the Medical Devices & Instruments industry
Industry Median: 26
vs CMEOF: 13.50
Creo Medical Group's EPS (Basic) for the
six
months ended in Dec. 2025 was $-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
Creo Medical Group (OTCPK:CMEOF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Creo Medical Group PE Ratio (TTM) Related Terms
Creo Medical Group PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group PE Ratio (TTM) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Creo Medical Group's Share Price of today is $0.20.
For company reported semi-annually, Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Creo Medical Group (CMEOF) has a PE Ratio (TTM) of 14.29 as of Jul. 02, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Creo Medical Group and its competitors. This is near median its historical median of 13.13. Over the past decade, Creo Medical Group's PE Ratio (TTM) has ranged from 10.15 to 17.75. According to the industry distribution chart, Creo Medical Group ranks #88 out of 435 companies in the Medical Devices & Instruments industry, placing it in the top 20.2%.
Is Creo Medical Group's PE Ratio (TTM) too high?
Creo Medical Group's current PE Ratio (TTM) of 14.29 is near median its 10-year median of 13.13. Over the past 10 years, this metric has ranged from a low of 10.15 to a high of 17.75. The Medical Devices & Instruments industry median PE Ratio (TTM) is 26.00. Creo Medical Group's value of 14.29 is 45% below this industry median. Based on the distribution chart, Creo Medical Group ranks #88 out of 435 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's PE Ratio (TTM) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #88 out of 435 companies for PE Ratio (TTM). This places Creo Medical Group in the top 20% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 26.00. Creo Medical Group's value of 14.29 is 45% below this benchmark. Historically, Creo Medical Group's own PE Ratio (TTM) has ranged from 10.15 to 17.75 over the past decade. While the company's 10-year median is 13.13 vs. the industry median of 26.00, Creo Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Devices & Instruments company?
The median PE Ratio (TTM) among Medical Devices & Instruments companies is 26.00, based on 435 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current PE Ratio (TTM) of 14.29 is 45% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio (TTM) is 26.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current PE Ratio (TTM) is 14.29, which is near median its own 10-year median of 13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current PE Ratio (TTM) of 14.29. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current PE Ratio (TTM) is 14.29, which is near median its 10-year median of 13.13 and 45% below the Medical Devices & Instruments industry median of 26.00. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current PE Ratio (TTM) is 14.29 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
PE Ratio (TTM): 14.29 (near median its 10-year median of 13.13)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
Industry Position: 45% below the Medical Devices & Instruments median (#88 of 435)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for CMEOF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
